CAR-T cells with the CD38(-)CD73(-)Tim-3(-)HLA-DR(+) phenotype predict the efficacy of tisagenlecleucel as a treatment for B cell precursor ALL.
具有 CD38(-)CD73(-)Tim-3(-)HLA-DR(+) 表型的 CAR-T 细胞可预测 tisagenlecleucel 作为 B 细胞前体 ALL 治疗药物的疗效。
期刊:Cell Reports Medicine
影响因子:10.6
doi:10.1016/j.xcrm.2025.102576
Mikami Takashi, Kato Itaru, Llamas-Covarrubias Mara Anais, Hiramatsu Hidefumi, Uchihara Yoshinori, Mitsuyoshi Takaya, Kitawaki Toshio, Saida Satoshi, Umeda Katsutsugu, Ogawa Seishi, Takaori-Kondo Akifumi, Wing James Badger, Takita Junko
